• Home
  • About Us
    • Company Profile
    • Enterprise Honor
    • Enterprise Qualification
    • Corporate Shareholder
  • Science & Innovation
    • Molecular Glue
    • GLUETAC
    • Degrader-Antibody Conjugates
    • Journal Articles
  • Pipeline
    • GT919
    • GT929
    • GT818
    • GT820
  • Partnerships
    • Local Cooperation
    • Out Licensing
    • Global Cooperation
    • University Cooperation
  • Subject Recruitment
    • Multiple myeloma
    • Non-Hodgkin’s lymphoma
  • Talent Strategy
    • Talent concept
    • Employee honor
    • Employee Showcase
    • Welfare system
    • Job Openings
    • Talent scheme
  • Press Releases
    • R&D advancements
    • Technology Platform
    • Media Coverage
  • Contact Us
    • China
    • USA
  • Home
  • About Us
    • Company Profile
    • Enterprise Honor
    • Enterprise Qualification
    • Corporate Shareholder
  • Science & Innovation
    • Molecular Glue
    • GLUETAC
    • Degrader-Antibody Conjugates
    • Journal Articles
  • Pipeline
    • GT919
    • GT929
    • GT818
    • GT820
  • Partnerships
    • Local Cooperation
    • Out Licensing
    • Global Cooperation
    • University Cooperation
  • Subject Recruitment
    • Multiple myeloma
    • Non-Hodgkin’s lymphoma
  • Talent Strategy
    • Talent concept
    • Employee honor
    • Employee Showcase
    • Welfare system
    • Job Openings
    • Talent scheme
  • Press Releases
    • R&D advancements
    • Technology Platform
    • Media Coverage
  • Contact Us
    • China
    • USA
中文English
中文English
Slide 1
Conference Preview|Gluetacs to Present
at Biotechnology in America 2024 (BIO)
Slide 1
Gluetacs Co-publishes Cover Article in Cell Chemical Biology
Slide 1
Gluetacs was awarded 2024 Lingang 'Science and Technology Innovation Elite' enterprise, and Dr. Xiaobao Yang, the founder of Gluetacs, was awarded the "Top 10 Pioneers in Science and Technology Innovation" in Lingang.
Slide 1
Three talents from Gluetacs successfully applied for the settlement subsidy in Lingang New Area!
Slide 1
Gluetacs Launches Flower Arrangement Activities for Women's Day
Slide 1
Annual Meeting Ceremony | Gluetacs 2024 Annual Meeting on the theme of "Innovating and Pioneering for the benefit of patients" was successfully held
Slide 1
Gluetacs Patent Awarded Top 100
in Shanghai High Value Patent Operation Competition 2023
Slide 1
Academician Peter ten Dijke and Professor Pang Baoxu from Leiden University Medical Center visited Gluetacs and discussed the progress of the cooperation project.
Slide 1
Shanghai News | What is the core competitiveness of ShanghaiTech's innovative biopharmaceutical company?
Slide 1
Gluetacs was honored as "Top 10 Small Molecule Innovative Drug Companies with the Most Growing Potential" in China Biopharmaceutical Science and Technology Innovation Value Ranking 2023.
previous arrow
next arrow
06 2024-03
Milestone! Gluetacs Therapeutics Commences First Patient Dosing in First-In-Human Phase I/IIa Trial to Assess GT929
27 2023-10
Gluetacs Therapeutics Announces IND Approval of Its Second Molecular Glue Degrader Pipeline GT929 from FDA
24 2023-07
Two Milestones: (1) Gluetacs Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial to Evaluate GT919; (2) Gluetacs Therapeutics Announces IND Approval of GT929 from China CDE 
19 2023-05
Gluetacs Therapeutics Announces Approval of IND Application from the FDA for GT919, an IKZF1/3 Targeted Immunomodulatory Drug Candidate
17 2023-05
Gluetacs Therapeutics jointly published an article in Journal of Biological Chemistry
« Previous 1 … 3 4 5 6 7 Next » 共 33 条
Enterprise Email

Gluetacs Therapeutics (Shanghai) Co., Ltd.

Building 20, Lane 218, Haiji 6th Road, Pudong District, Shanghai, China

Zip Code: 201306

Tel: +86-21-58162368

Copyright © Gluetacs Therapeutics (Shanghai) Co., Ltd. 沪ICP备2021038033号-3

沪公网安备 31011502001234号

Wechat Offical Account

Scan & Follow Us